The drug Orlistat (XenicalTM), which was developed as an inhibitor of gastric and pancreatic lipases and has been approved for weight loss by the FDA, blocks breast cancer cell cycle progression, promotes apoptotic cell death, and transcriptional repression of the HER2 oncogene [25]. Here, ERBB2 is linked to breast cancer.